Targeted Cancer Therapies

What Makes a Therapy Targeted?

Traditional chemotherapy works by killing rapidly dividing cells — a relatively non-selective approach that damages cancer cells but also harms healthy tissues. Targeted therapies, by contrast, are designed to interfere with specific molecules (usually proteins) that play defined roles in cancer cell growth, survival, or spread.

The concept depends on identifying a molecular driver — a protein or pathway that the cancer cell depends on for survival, but that normal cells either do not express or express at lower levels. The drug is then designed to block or alter that specific target.

"Targeted" does not mean side-effect-free. It means the mechanism of action is directed at a defined molecular target rather than broadly at cell division. Side effects still occur, but they often differ in character from classic chemotherapy toxicities.

Small-Molecule Targeted Drugs

Small-molecule targeted drugs are chemically synthesized compounds small enough to enter cells and act on intracellular targets. Many are kinase inhibitors — molecules that block enzymes called kinases, which are switches that turn on cell growth and survival signals.

Kinases were recognized as cancer drug targets when researchers discovered that many cancers harbor mutant kinases that are permanently switched on, driving uncontrolled proliferation. Blocking these mutant kinases selectively kills cancer cells more than normal cells.

Key subtypes: - Tyrosine kinase inhibitors (TKIs): Block specific receptor tyrosine kinases (e.g., EGFR, ALK, BCR-ABL, HER2, VEGFR, FGFR). - CDK4/6 inhibitors: Block cell cycle proteins that control entry into DNA replication (e.g., palbociclib, ribociclib, abemaciclib for breast cancer). - PARP inhibitors: Block a DNA repair enzyme; most effective in cancers with BRCA mutations that already have impaired DNA repair (e.g., olaparib, niraparib). - PI3K/AKT/mTOR inhibitors: Target a key signaling pathway frequently dysregulated in cancer.

Biologic Targeted Therapies

Biologic targeted therapies are larger molecules, typically monoclonal antibodies, that cannot enter cells but act on surface receptors or extracellular signaling molecules.

• Receptor-blocking antibodies: Bind to receptors on cancer cell surfaces and block growth-factor binding (e.g., trastuzumab blocks HER2, cetuximab blocks EGFR).
• VEGF-targeting antibodies: Block vascular endothelial growth factor or its receptor, starving tumors of blood supply (e.g., bevacizumab).
• Immune checkpoint inhibitors: Antibodies that block inhibitory signals (PD-1/PD-L1, CTLA-4) that cancer cells use to suppress T-cell attack. These are now considered a standard pillar of cancer therapy.
• Bispecific antibodies: Engineered to bind two different targets simultaneously, bringing T cells into proximity with cancer cells (e.g., blinatumomab, which links T cells to CD19-positive leukemia cells).

Receptor SelectivityReceptor Selectivity

The ability of a drug to preferentially bind to and affect one specific receptor type over others. Higher selectivity generally means fewer side effects because the drug acts more precisely on its int

and Resistance

Receptor selectivity — how precisely a drug binds its intended target versus other similar receptors — is a key design parameter. High selectivity reduces off-target side effects. However, cancer cells are genetically unstable and often develop resistance by acquiring new mutations in the target protein that prevent drug binding, by upregulating alternative pathways, or by losing the target protein altogether.

Second-generation and third-generation inhibitors are designed to overcome resistance mutations. For example, first-generation EGFR inhibitors (gefitinib, erlotinib) are defeated by the T790M resistance mutation; osimertinib (a third-generation TKI) was specifically designed to block T790M-mutant EGFR.

Combination approaches — using two targeted agents simultaneously or sequencing them — are standard practice to delay resistance.

Biomarker Testing Before Treatment

Targeted therapies only work in patients whose tumors express the relevant target. This makes biomarker testing before treatment selection essential. Testing may include:

• Immunohistochemistry (IHC): Detects protein expression on tumor tissue (e.g., HER2 protein levels).
• Fluorescence in situ hybridization (FISH): Detects gene amplification (e.g., HER2 gene copies).
• Next-generation sequencing (NGS): Comprehensive genomic profiling that identifies mutations, fusions, and copy number changes across hundreds of cancer-relevant genes simultaneously.
• Liquid biopsy: Analysis of circulating tumor DNA in blood, useful for monitoring response and detecting resistance mutations without repeat biopsies.

The FDA has approved companion diagnostics — tests that must be performed to identify patients eligible for a specific targeted therapy.

Major Targeted Therapy Examples

• Imatinib (Gleevec): BCR-ABL kinase inhibitor for chronic myeloid leukemia (CML) caused by the Philadelphia chromosome translocation. Transformed CML from a fatal disease to a manageable chronic condition.
• Trastuzumab (Herceptin): HER2-blocking antibody; dramatically improves outcomes in HER2-positive breast and gastric cancers.
• Osimertinib (Tagrisso): EGFR TKI for EGFR-mutant non-small cell lung cancer; first-line standard of care.
• Vemurafenib/Dabrafenib: BRAF V600E inhibitors for melanoma with this specific mutation.
• Venetoclax: BCL-2 inhibitor for CLL and AML; targets the anti-apoptotic machinery cancer cells rely on for survival.

Side Effects of Targeted Therapies

Targeted therapies have distinct toxicity profiles compared to chemotherapy. Because they affect specific pathways rather than all dividing cells, traditional chemotherapy side effects (hair loss, severe nausea, bone marrow suppression) are often less prominent. However, targeted drugs introduce their own adverse effects:

• EGFR inhibitors: Acneiform skin rash, diarrhea, paronychia (nail inflammation).
• VEGF pathway inhibitors: Hypertension, wound healing impairment, risk of arterial thrombosis, rare bowel perforation.
• CDK4/6 inhibitors: Neutropenia (usually manageable), fatigue, QTc prolongation.
• Checkpoint inhibitors: Immune-related adverse events (irAEs) — the immune system attacks normal tissues including the lung (pneumonitis), liver (hepatitis), gut (colitis), and endocrine organs.

Key Takeaways

• Targeted therapies attack specific molecular drivers of cancer rather than all rapidly dividing cells.
• Small-molecule drugs (kinase inhibitors, PARP inhibitors) act inside cells; biologic drugs (antibodies) act on cell surfaces or extracellular targets.
• Biomarker testing is essential — targeted therapies only work in patients whose tumors express the relevant target.
• Resistance is a major challenge; sequential or combination strategies are standard.
• Side effects differ from chemotherapy and are specific to the pathway inhibited (skin rash, hypertension, immune-related effects rather than hair loss and severe nausea).